Adaptimmune Therapeutics plc (Nasdaq: ADAP)

https://www.adaptimmune.com

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the Company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. As of October 31, 2015, 86 patients had been treated with Adaptimmune’s NY-ESO affinity enhanced T-cell therapy: 48 under Adaptimmune’s IND, and 38 under a National Cancer Institute IND. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next affinity enhanced T-cell therapy, directed at MAGE-A10, is scheduled to enter the clinic shortly. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 of these through unpartnered research programs. Adaptimmune has over 190 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. *

	Start	2015-05-01 renamed date ca
	Group	Adaptimmune (Group)
	Predecessor	Adaptimmune Ltd.
	Industry	BIOTECH
	Industry 2	TCR engineered T-cells
	Person	Rawcliffe, Adrian (Ad) (Adaptimmune 201909– CEO joined 201503 as CFO before GSK)
	Person 2	Knowles, Jonathan (Adaptimmune 201311– Executive Board Chairman before non-exec Director + Roche Head Global Research)

	Region	Abingdon, Oxfordshire
	Country	United Kingdom (GB)
	Street	101 Park Drive Milton Park
	City	OX14 4RY Abingdon, Oxfordshire
	Tel	+44-1235-430000
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2017-12-31)
	Currency	GBP
	Annual sales	59,505,000 (revenue, consolidated (2018) 2018-12-31)
	Profit	-95,514,000 (2018-12-31)
	Cash	205,134,000 (2018-12-31)

		* Document for »About Section«:

		Record changed: 2024-10-12